49 results about "TNM Staging" patented technology

The invention aims to provide a reagent capable of detecting the expression condition of a target protein in a paraffin-embedded tissue, and particularly provides a kit used for evaluating the prognosis information of a patient suffering from the esophageal squamous cell carcinoma. The kit comprises antibodies of the three target proteins, namely Annexin II, Kindlin-2 and Myosin-9, and further comprises goat serum, 0.01 M citrate repair liquid, 3% H2O2, a Polymer reinforcing agent, a Polymer, a DAB color reagent and a PBS solution. The kit can be used for evaluating the prognosis of the patient; compared with the international TNM staging, the kit is simpler and easier to use, and higher in both sensitivity and specificity, and is more suitable for the prognosis evaluation of Chinese suffering from the esophageal squamous cell carcinoma.

The invention discloses a multi-scale technology-based tumor texture feature extraction method. The method includes the following steps that: tumor PET image data are obtained from clinic, an ideal tumor treatment region is drawn; segmentation is carried out according to the boundary of the drawn target region, and gross tumor volume (GTV) is extracted, and PET images only containing the GTV are obtained; gray level quantization is performed on each PET image, and two-dimensional dual-tree complex wavelet transform is performed on the quantized images, and a plurality of sub-band images can be obtained from each image; all the sub-band images which are obtained by decomposing the PET images are re-combined into new stereo GTV; the mean and variance of a detail coefficient matrix obtained after two-dimensional dual-tree complex wavelet transform are calculated, and tumor texture feature values are calculated; and the relationships among the maximum values (SUVmax) of the tumor texture feature values and standardized uptake values, tumor TNM stages and infiltration depth are established, and the heterogeneous texture feature values of a quantized tumor are screened and optimized.

The invention relates to the field of bioengineering and tumor markers, in particular to a marker for locally advanced esophageal squamous cell carcinoma prognosis and an application of the marker. The marker is a combined marker consisting of one or more of miR-135b-5p, miR-139-5p, miR-29c-5p and miR-338-3p, and locally advanced esophageal squamous cell carcinoma prognosis is predicted by detecting expression levels of the four miRNA in tumor tissue and performing calculation according to a formula (0.4690*miR-135b-5p expression level)+(0.3839*miR-139-5p expression level)+(0.1733*miR-29c-5p expression level)+(0.3368*miR-338-3p expression level). The combined marker has the advantages of good stability and high sensitivity and specificity and can more accurately and more valuably evaluateprognosis of patients than traditional clinical pathological factors such as TNM (tumor-node-metastasis) staging and the like. On one hand, the molecular marker related to esophageal squamous cell carcinoma prognosis is provided, on the other hand, an esophageal squamous cell carcinoma prognosis prediction model is established, so that individual treatment of esophageal squamous cell carcinoma isrealized, the comprehensive treatment level of the esophageal squamous cell carcinoma is improved, the life quality of esophageal squamous cell carcinoma patients is improved, and the lifetime of theesophageal squamous cell carcinoma patients is prolonged.

The invention relates to the technical field of lung cancer gene detection, in particular to an ANXA3 gene or an ANXA3 protein as a biomarker of lung adenocarcinoma. Research findings, ANXA3 gene wasabnormally expressed in lung adenocarcinoma in both Xuanwei and non-Xuanwei areas. The expression of ANXA3 gene was lower or higher than normal level. ANXA3 gene or protein could be used as biomarkerof lung adenocarcinoma to diagnose lung adenocarcinoma, judge lymph node metastasis, assist TNM staging and prognosis. The invention provides an ANXA3 gene and an expression product thereof in preparation for prejudging whether lymph node metastasis of lung adenocarcinoma, The present invention provides a new diagnostic method for clinically diagnosing metastasis of lung adenocarcinoma and provides a new candidate drug for treating metastasis of lung adenocarcinoma. The present invention relates to a method for treating metastasis of lung adenocarcinoma and a pharmaceutical composition for treating lung adenocarcinoma.

The invention discloses the application of NFI transcription factors in esophageal squamous cell carcinoma, and particularly relates to the application of a transcription factor NFIB in the diagnosisof esophageal squamous cell carcinoma and the application of a transcription factor NFIA in evaluating the differentiation degree, TNM staging and prognosis of esophageal squamous cell carcinoma. Thelevel of the NFI transcription factors of esophageal squamous cell carcinoma is detected and analyzed by the immunohistochemical technique, it is found that patients with high expression of NFIA havea low tumor differentiation degree, a high TNM stage and poor prognosis, and high expression of NFIB corresponds to a low esophageal squamous cell carcinoma tissue differentiation degree, in this way,a new way is provided for the diagnosis and prognosis judgment of esophageal squamous cell carcinoma, and a reference is provided for clinicians to analyze the condition of patients with esophageal squamous cell carcinoma.

The invention discloses an application of ABHD6 in diagnosis, prognosis and treatment products of non-small cell lung cancer. The invention discloses a monoacylglycerol hydrolase ABHD6 (alpha / beta-hydrolase-domain-containing 6). The results of tissue microarray showed that the expression of ABHD6 in tumor tissues was significantly higher than that in adjacent tissues, and the high expression of ABHD6 was related to lymph node metastasis and TNM staging in non-small cell lung cancer, which was an independent factor of poor prognosis in NSCLC. The application of ABHD6 in diagnosis, prognosis andtreatment products of non-small cell lung cancer can influence the invasion and migration of non-small cell lung cancer cells in vitro by silencing ABHD6, and can slow down the growth speed of the tumor and slow down the process of the tumor migration to the lung.

The invention provides a staining kit for all pathological tissue sections (especially lung cancer TNM staging) and a use method thereof. According to the staining kit and the use method thereof, immunohistochemical staining and special staining are combined for application, two staining modes can be completed on the same slice, staining time is shortened, displayed information amount is far larger than signals and information amount provided by traditional separate single staining, missed diagnosis of tiny infiltration is avoided, effective help can be provided for clinical later treatment, an important diagnosis basis is provided for defining clinical stages of a patient, and whether vascular tumor embolism exists in other types of tumors or not can be accurately judged. If other types of markers are selected, the markers can also be used as an index for cardiovascular disease discrimination.

The invention belongs to the fields of function and application of genes and RNA, and relates to application of an MACC1-AS1 probe to preparation of a diagnostic reagent for predicting clinical prognosis of gastric cancer. The invention also provides a diagnostic kit for predicting clinical prognosis of gastric cancer. The kit comprises the MACC1-AS1 probe. The invention discloses that in the gastric cancer, the MACC1-AS1 is related to the prognosis of a patient suffering from the gastric cancer and is in positive correlation with clinical staging and TNM staging of the patient for the first time; and the MACC1-AS1 is an important molecule which generates anti-oxidation substances to maintain redox balance, promotes glycolysis to maintain glycometabolism, maintains survival and reduces apoptosis when the gastric cancer cells do not have sugar stress. Therefore, the invention provides theoretical basis and clinic basis for research of clinical prognosis related factors of the patient suffering from the gastric cancer and clinical application of non-coding RNA.

The invention is a kit for detecting the expression of paraffin-embedded surgical specimens of patients with esophageal cancer in combination with 5-lipoxygenase metabolic pathway protein antibodies, and then predicting the prognosis of patients. The kit includes antibodies ‑5‑LO, FLAP, and LTA4H antibodies for 3 target proteins, as well as goat serum, 0.01M citrate repair solution, 3% H2O2, Polymer enhancer, Polymer polymer, DAB chromogenic reagent, PBS solution. However, the kit of 5-lipoxygenase metabolic pathway protein used in the present invention to jointly predict the patient's prognosis has a higher predictive effect than single index detection, second only to the predictive ability of TNM staging, and the immune tissue based on the present invention The chemical hypersensitivity two-step method is a mature and reliable method that can be widely used in primary hospitals.

The invention provides a pull-out scale device for international TNM staging of esophageal squamous cell carcinoma, which is composed of a rectangular hollow sleeve with openings at both ends and a pumping plate marked with staging results. The pumping plate is inserted into the hollow sleeve. The cover is suitable, and there are a first rectangular window and a second rectangular window on the front of the hollow cover, and a semicircular notch is provided in the middle of the two ends of the opening of the central control cover to facilitate the movement of the pumping plate. On the back and front of the hollow sleeve, relevant definitions of each staging variable are printed. The present invention is displayed in the form of an intuitive ruler, helps clinicians to accurately and quickly stage, and is conducive to remembering new stage regulations as soon as possible. Adjuvant treatment is recommended as early as possible for patients with late stage, and the most appropriate comprehensive treatment plan should be selected. At the same time, strengthen postoperative follow-up monitoring, timely detection of local and distant metastasis, and prolong survival. And it is convenient to make a better treatment plan in the follow-up, and form an objective index that is helpful to effectively evaluate the curative effect.

The invention discloses a biomarker for evaluating the therapeutic effect of esophageal squamous cell carcinoma (ESCC) neoadjuvant chemoradiotherapy (nCRT) and application of an MMP12 protein as the biomarker in preparation of a reagent, kit or detection device for evaluating the rapeutic effect of ESCC nCRT. The abnormal expression level of MMP12 is significantly related to TNM staging, lymph node metastasis and survival time (P is less than 0.05) of ESCC, a new biomarker for predicting nCRT response of an ESCC patient is determined through microarray data analysis, and the MMP12 may be a useful tumor biomarker and a treatment target for the ESCC patient.

The invention belongs to the technical field of biology, and relates to application of phosphatase PHLPP2 as a biomarker, in particular to an application of PHLPP2 in preparation of a prognostic marker preparation for treating pancreatic cancer through vitamin C. The PH structural domain of the phosphatase is rich in leucine repeat protein phosphatase 2, and corresponding conserved sites of Akt, RAF1 and the like can be directly dephosphorylated, so that cell apoptosis is promoted, and cell proliferation and migration are inhibited; the tests show that the expression level of the PHLPP2 is reduced, the killing effect of the vitamin C on pancreatic cancer tumors can be inhibited, the high expression of the PHLPP2 is positively related to the lifetime of a patient and is negatively related to TNM staging, and the PHLPP2 can be used as a potential biomarker of the vitamin C for treating the pancreatic cancer and is further used for preparing a prognosis marker preparation of the vitamin C for treating the pancreatic cancer.